Bull case
Fractyl Health is viewed favorably because Revita has shown unusually durable post-GLP-1 weight maintenance after a single minimally invasive procedure, with REVEAL-1 patients retaining about 78% of prior drug-induced weight loss at one year and 100% of participants staying within 10% regain at six months. The thesis is reinforced by a clear dose-response signal from ablation length, supportive cardiometabolic improvements, and the company’s belief that the pivotal REMAIN-1 cohort is powered with more than 300 patients and over 90% power, positioning the 3Q26 midpoint readout and 4Q26 pivotal data as meaningful catalysts. Financially and strategically, the company says cash runway extends into early 2027, while FDA feedback, potential De Novo classification, and the RAPID pathway could reduce regulatory and reimbursement friction, improving commercialization odds.